TABLE 2

Pharmacokinetics of JM6 and Ro-61-8048 in mice after oral administration alone or in combination

GroupAnalyte Dosed (Dose Level)Analyte MeasuredAUClastAUCinfAUCNFCmaxCmaxNTmaxt1/2
nM × hnM × h × kg/mg%nMh
IJM6 (10 mg/kg)aJM6110011001107.21001100.51.1
Ro-61-804820002300N.C.N.C.230N.C.4.0b6.6
IIRo-61-8048 (0.05 mg/kg) with JM6 (9.5 mg/kg)aJM6150015001609.814001500.50.9
Ro-61-804849,00053,000110,000N.C.900018,0000.5b6.9
IIIRo-61-8048 (1.0 mg/kg) with JM6 (9.0 mg/kg)JM6110011001307.810001100.50.7
Ro-61-8048110,000110,000140,000N.C.17,00021,0000.5b4.4
IVRo-61-8048 (0.05 mg/kg) aloneRo-61-80484300450090,0007055011,0000.5b5.2
VRo-61-8048 (0.05 mg/kg) with JM6 (10 mg/kg)aJM6130013001301319001900.50.7
Ro-61-804849005200100,0008053011,0001.0b5.8
VIRo-61-8048 (0.05 mg/kg) with JM6 (25 mg/kg)aJM648004800190N.C.34001400.50.7
Ro-61-804884008800180,000N.C.80016,0002.0b5.2
VIIRo-61-8048 (0.05 mg/kg) with JM6 (50 mg/kg)aJM696009600190N.C.81001900.50.7
Ro-61-80487900N.C.160,000N.C.19,000160,0004.0b6.5
  • N.C., not calculated.

  • a JM6 in the dose contained <0.4% of Ro-61-8048.

  • b The Tmax for Ro-61-8048 is observed between 0.5 and 4 h and is difficult to define precisely in nonserial studies because of the leveled protracted plasma concentration versus time curve driven by the slow Clp.